Constellation Pharmaceuticals Provides Update of MANIFEST Study for CPI-0610 at ASH Meeting
December 06, 2020 08:00 ET
|
Constellation Pharmaceuticals , Inc.
67% spleen volume response rate observed in 63 first-line myelofibrosis patients treated with CPI-0610 + ruxolitinib at 24 weeksCPI-0610 demonstrated activity, both as a monotherapy and as add on to...
Constellation Pharmaceuticals to Host Analyst / Investor Event to Discuss Update of MANIFEST Clinical Trial for CPI-0610 Presented at ASH Meeting
November 23, 2020 13:00 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and...
Constellation Pharmaceuticals Announces Third-Quarter 2020 Financial Results
October 29, 2020 07:00 ET
|
Constellation Pharmaceuticals , Inc.
MANIFEST data update planned for the American Society of Hematology (ASH) meeting in December CAMBRIDGE, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a...
Constellation Pharmaceuticals to Host Conference Call to Discuss Third Quarter 2020 Results
October 19, 2020 14:00 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop...
Constellation Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences
September 09, 2020 15:00 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to...
Constellation Pharmaceuticals Announces Second-Quarter 2020 Financial Results, Provides Regulatory Update
August 05, 2020 07:00 ET
|
Constellation Pharmaceuticals , Inc.
Constellation has aligned with the FDA on the design of MANIFEST-2, the pivotal Phase 3 clinical trial for CPI-0610 expected to begin in 2H20Constellation plans to explore additional indications for...
Constellation Pharmaceuticals to Host Conference Call to Discuss Second Quarter 2020 Results
July 31, 2020 12:00 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., July 31, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop...
Constellation Pharmaceuticals Announces Pricing of Public Offering of Common Stock
June 16, 2020 20:27 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., June 16, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., (Nasdaq: CNST) a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
Constellation Pharmaceuticals Announces Proposed Public Offering of Common Stock
June 15, 2020 16:01 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., June 15, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., (Nasdaq: CNST) a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
Constellation Pharmaceuticals Provides Updates of MANIFEST Study for CPI-0610 and EZH2 Franchise
June 12, 2020 02:30 ET
|
Constellation Pharmaceuticals , Inc.
Spleen response rates in first-line patients at 12 weeks and 24 weeks in line with previously reported data and differentiated from standard of careSpleen responses demonstrated in...